suPAR: A New Biomarker for Cardiovascular Disease?
- 1 October 2015
- journal article
- review article
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 31 (10) , 1293-1302
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk Fonden
This publication has 51 references indexed in Scilit:
- Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk ScoreInternational Journal of Cardiology, 2013
- NT-proBNP, C-Reactive Protein and Soluble uPAR in a Bi-Ethnic Male Population: The SAfrEIC StudyPLOS ONE, 2013
- Soluble Urokinase Plasminogen Activator Receptor is Associated With Inflammation in the Vulnerable Human Atherosclerotic PlaqueStroke, 2012
- Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic reviewIntensive Care Medicine, 2012
- Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Mortality and Cardiovascular Events in the General Community: A 9-Year Follow-up StudyMayo Clinic Proceedings, 2011
- Statistical methods for assessment of added usefulness of new biomarkersClinical Chemistry and Laboratory Medicine (CCLM), 2010
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signalingFEBS Letters, 2009
- Criteria for Evaluation of Novel Markers of Cardiovascular RiskCirculation, 2009
- Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesionsBlood Coagulation & Fibrinolysis, 2004